A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Surgical Innovation Associates Reports 1st US Patient Implanted in Pivotal IDE Study of DuraSorb Monofilament Mesh Use in Prosthetic Breast Reconstruction

Surgical Innovation Associates, (SIA) an early growth-stage medical technology company, announced today that the first patient has been enrolled in a pivotal trial of its flagship absorbable mesh, DuraSorb, under an investigational device exemption (IDE) from the United States Food and Drug Administration (US FDA).

Surgical Innovation Associates notes the study will evaluate the safety and effectiveness of DuraSorb for reinforcement in prosthetic breast reconstruction.

The product is made from a biocompatible synthetic material to provide mechanical support and scaffolding during the early months of wound healing and scar formation, followed by gradual absorption, which is generally complete by one year.1-4 While DuraSorb® received a CE mark for reconstructive and aesthetic breast surgery last year, no mesh product, DuraSorb or otherwise, currently has approval from the US FDA for breast reconstruction. Despite this, prosthetic breast reconstruction is most often performed with costly biologic mesh derived from the skin of human cadavers.5-7 DuraSorb® is designed to provide the same type of support during breast reconstruction, without requiring any cadaveric or animal-derived tissue.

“As plastic surgeons, we have been using processed human skin in breast surgery for over 15 years,” said Dr. Mihye Choi, an Associate Professor at New York University Hansjorg Wyss Department of Plastic Surgery, and the first principal investigator to enroll a patient in SIA’s pivotal study. “ADM has its benefits, but I am excited to use a non-biologic alternative that has been evaluated by the FDA for this specific purpose.”

The importance of this work is recognized by the National Cancer Institute, which is partially funding the clinical trial through the Small Business Innovation Research Program. In addition, the IDE study was approved by the Centers for Medicare and Medicaid, which will allow Medicare beneficiaries access to the trial.

“After years of collaborative work with FDA on a study design, we are honored to initiate this trial with some leading minds in the field of plastic surgery,” said Dr. Alexei Mlodinow, President and CEO of Surgical Innovation Associates. “This work will move the field forward, with important implications for a population of women who are going through enough as it is following a diagnosis of breast cancer and the need for a mastectomy.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy